CJC-1295 + Ipamorelin: The Research
Hormonal, Growth Hormone & Body Composition Research
Ipamorelin, the secretagogue half of the CJC-1295 + ipamorelin pairing, has a clean human pharmacology record — and an honest one, because not every trial hit its target. Two published studies tell both sides.
View product →Findings
- In the first study of ipamorelin, it produced a clear, dose-dependent release of growth hormone.
- Ipamorelin was selective: growth hormone rose without meaningful rises in stress or lactation hormones.
- In studies, CJC-1295 raised growth hormone and IGF-1, with effects lasting days after a single dose.
- The blend combines two different triggers of the same system, which is exactly why the pair is studied together.
The human PK study (Pharm Res, 1999)
Gobburu and colleagues ran a dose-escalation trial in healthy male volunteers, with eight subjects at each of five infusion rates. Ipamorelin induced growth-hormone release at every dose level, as a single episode peaking around 40 minutes and declining exponentially. The pharmacokinetics were dose-proportional, with a short 2-hour half-life. In plain terms: the compound does, measurably, what it is designed to do in humans.
The postoperative-ileus trial (Int J Colorectal Dis, 2014)
A multicenter, double-blind, placebo-controlled Phase 2 trial gave 114 bowel-resection patients intravenous ipamorelin or placebo twice daily. Ipamorelin was well tolerated, and median time to first tolerated meal was shorter (25.3 vs 32.6 hours), but the difference did not reach statistical significance (P=0.15). The honest reading: safe, promising direction, endpoint not met.
What CJC-1295 and ipamorelin are
The two are studied together because they hit the growth-hormone axis by different routes. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue; ipamorelin is a ghrelin-receptor agonist, a growth-hormone secretagogue. Our CJC-1295 + Ipamorelin (No-DAC) explainer and our comparison with tesamorelin cover the pairing.
Vistara Labs stocks the CJC-1295 + Ipamorelin blend as research vials, shipped from within Canada to every province.
Frequently asked questions
What does the data on ipamorelin show?
A human pharmacokinetic study in healthy volunteers showed ipamorelin reliably stimulates a single pulse of growth-hormone release at every dose tested, with dose-proportional kinetics and a short half-life of about 2 hours.
Did ipamorelin work in its surgical trial?
It was safe but did not beat placebo on the key endpoint. In a Phase 2 trial for postoperative ileus after bowel surgery, ipamorelin was well tolerated but showed no significant efficacy difference versus placebo on time to first tolerated meal.
Why are CJC-1295 and ipamorelin paired?
They act on the growth-hormone axis by complementary mechanisms — CJC-1295 as a GHRH analogue, ipamorelin as a ghrelin-receptor agonist (secretagogue) — which is why the research community studies them together.
Sources: Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999;16:1412-1416. PMID 10496658. Beck DE, et al. Ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-1534. PMID 25331030.
References
The published human CJC-1295 trial used the long-acting DAC analogue, not the no-DAC form. Ipamorelin has its own human pharmacokinetic study. No trial of the two combined was identified.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsRandomised placebo-controlled trial in healthy adults — of the LONG-ACTING (DAC) CJC-1295 analogue, not the no-DAC form.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersHuman pharmacokinetic/pharmacodynamic study; five escalating infusion levels, eight healthy male subjects per level.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
